AusBiotech 2013 national conference opens in Brisbane with industry awards
31 October, 2013Brisbane yesterday welcomed the official launch of the AusBiotech 2013 national conference - a premier event on the Australia and Asia-Pacific calendar - recognising world-class leaders in the biotechnology industry with the Janssen Industry Excellence Awards.
Nexvet secures $7m in capital raising
30 October, 2013 by Dylan Bushell-EmblingNexvet has closed an oversubscribed capital raising, taking in an extra $7m to support its veterinary biological drug development programs.
Industry body MTAA names newest board
29 October, 2013 by Dylan Bushell-EmblingMedical technology industry body MTAA has announced the appointment of three new board members, and the departure of two more who have served their maximum six-year term.
New guide launched at major life science investor event
29 October, 2013The Victorian Minister for Technology, the Hon Gordon Rich-Phillips, yesterday launched the new 'Guide for Life Science Company Directors' at the opening of Australia’s biggest biotech investment event in this part of the world to date - Australia Biotech Invest 2013.
Mesoblast close to milestone payments from Japan deal
28 October, 2013 by Dylan Bushell-EmblingA Japanese licensee to Mesoblast's MSC technology will soon file for regulatory approval in the market for a treatment for steroid-refractory GvHD.
ResMed lifts September quarter profit by 14%
28 October, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) said its revenue for the September quarter increased 5%, despite what CEO Mick Farrell called a "tough competitive product cycle".
Biotron posts early data from HIV/HCV trial
25 October, 2013 by Dylan Bushell-EmblingDuring a phase II trial, Biotron's (ASX:BIT) BIT225 has shown promise at enhancing antiviral activity in hard-to-treat HCV Genotype 3 patients undergoing the IFN/RVB treatment regimen.
FDA clears first drug from UWA spinout iCeutica
25 October, 2013 by Dylan Bushell-EmblingiCeutica has won FDA approval for Zorvolex, the first drug developed using a technology platform conceived at the University of Western Australia.
Allied Healthcare closes $10.4m rights offer
24 October, 2013 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) has raised $10.4m in a rights issue to help fund commercialisation efforts for its CardioCel heart patch.
Australian Export Council conducts in-depth survey on exports
24 October, 2013To better understand the export behaviour of Australian companies and help shape Australia's future trade agenda, the Australian Export Council is conducting Australia's International Business Survey.
Phosphagenics' oxymorphone patch storms phase I
24 October, 2013 by Dylan Bushell-EmblingShares in Phosphagenics (ASX:POH) climbed 42% after the company reported strong plasma concentrations from the first in-human trial of opioid pain patch TPM/oxymorphone.
Challenges in the biotech business
23 October, 2013 by Susan WilliamsonEstablishing a small biotech company and getting products to market are just some of the challenges facing companies in the Australian biotech sector.
Immuron granted US Travelan patent
23 October, 2013 by Dylan Bushell-EmblingImmuron (ASX:IMC) has secured a US patent covering products developed with its colostrum platform technology, as it progresses with talks to bring Travelan to the US.
Last chance to register for the biotech industry event of the year: AusBiotech 2013
22 October, 2013Brisbane will welcome more than 1000 of the brightest brains in biotechnology and innovation next week for the official launch of the AusBiotech 2013 national conference; a premier event on the Australian and Asia-Pacific calendar.
pSivida shares slide after third FDA knockback
22 October, 2013 by Dylan Bushell-EmblingThe US FDA has for the third time rejected pSivida (ASX:PVA) licensee Alimera Sciences' NDA for diabetic macular edema treatment Iluvien.
